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Abstract
Background: Neuropathic pain is a highly debilitating chronic pain following damage to peripheral sensory neurons and is
often resistant to all treatments currently available, including opioids. We have previously shown that peripheral nerve
injury induces activation of cytosolic phospholipase A2 (cPLA2) in injured dorsal root ganglion (DRG) neurons that contribute
to tactile allodynia, a hallmark of neuropathic pain. However, lipid mediators downstream of cPLA2 activation to produce
tactile allodynia remain to be determined.
Principal Findings: Here we provide evidence that platelet-activating factor (PAF) is a potential candidate. Pharmacological
blockade of PAF receptors (PAFRs) reduced the development and expression of tactile allodynia following nerve injury. The
expression of PAFR mRNA was increased in the DRG ipsilateral to nerve injury, which was seen mainly in macrophages.
Furthermore, mice lacking PAFRs showed a reduction of nerve injury-induced tactile allodynia and, interestingly, a marked
suppression of upregulation of tumor necrosis factor a (TNFa) and interleukin-1b (IL-1b) expression in the injured DRG,
crucial proinflammatory cytokines involved in pain hypersensitivity. Conversely, a single injection of PAF near the DRG of
naı ¨ve rats caused a decrease in the paw withdrawal threshold to mechanical stimulation in a dose-dependent manner and
an increase in the expression of mRNAs for TNFa and IL-1b, both of which were inhibited by pretreatment with a PAFR
antagonist.
Conclusions: Our results indicate that the PAF/PAFR system has an important role in production of TNFa and IL-1b in the
DRG and tactile allodynia following peripheral nerve injury and suggest that blocking PAFRs may be a viable therapeutic
strategy for treating neuropathic pain.
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Introduction
Neuropathic pain that occurs after nerve injury results from an
aberrant functioning of a pathologically altered nervous system
[1,2]. A hallmark of neuropathic pain syndrome is tactile
allodynia, an abnormal hypersensitivity to innocuous stimuli,
which is often resistant to all treatments currently available,
including potent analgesic opioid drugs. The underlying mecha-
nisms by which nerve injury develops tactile allodynia have
remained largely unknown. The dorsal root ganglion (DRG)
contains cell bodies of primary afferent neurons that transmit
sensory information from the periphery to the central nervous
system. The activation of signal transduction cascades and the
transcriptional changes in the DRG and the resultant alterations in
the transmission properties of sensory neurons following peripheral
nerve injury might be involved in modulation of pain signaling in
acute and chronic pain conditions [2,3].
We have previously shown that peripheral nerve injury induces
activation of cytosolic phospholipase A2 (cPLA2), a Ca
2+-
dependent subclass of the PLA2 family [4] that is required for
tactile allodynia [5], in DRG neurons. However, the way in which
activated cPLA2 participates in tactile allodynia remains unknown.
cPLA2 is a crucial enzyme that catalyzes the hydrolysis of
phospholipids to release arachidonic acid and lysophospholipid,
and subsequently generates lipid mediators. Arachidonic acid is
metabolized to prostaglandins by the cyclooxygenase (COX)
pathway and to leukotrienes by the lipoxygenase (LOX) pathway.
Lysophospholipid can be converted to platelet-activating factor
(PAF) by lyso-PAF acetyltransferase and to lysophosphatidic acid
(LPA) by lysophospholipase D. It raises the possibility that these
lipid mediators mediated by cPLA2 activation may be secreted
from DRG neurons and, in turn, may modulate the excitation of
DRG neurons directly or indirectly. Indeed, prostaglandins have
been shown to cause sensitization of peripheral sensory neurons
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10467(peripheral sensitization) [6] and to produce allodynic behavior
[7,8]. LOX products activate capsaicin receptors in primary
sensory neurons, resulting in the induction of peripheral
sensitization [9,10]. Furthermore, PAF injected into the hindpaw
of naı ¨ve animals produces nociceptive responses and mechanical
hypersensitivity [11], and recent works have also shown that
intrathecal administration of LPA [12] and PAF [13,14] in naı ¨ve
animals induces tactile allodynia. However, the role of these lipid
mediators in the pathogenesis of neuropathic pain is not fully
understood.
In the present study, to determine the neuropathic pain-related
lipid mediators downstream of cPLA2 activation in the DRG, we
investigate the involvement of enzymes and lipid mediator
receptors in nerve injury-induced tactile allodynia using pharma-
cological, molecular, and genetic approaches. We further
investigated the role of the lipid mediator receptors in the
expression of tumor necrosis factor a (TNFa) and interleukin-1b
(IL-1b) in the DRG, proinflammatory cytokines that are strongly
implicated in nerve injury-induced tactile allodynia [15,16,17,18].
Results
Effects of COX and LOX inhibitors on the development of
tactile allodynia after nerve injury
To determine an involvement of a COX-dependent pathway in
tactile allodynia, we first performed double-immunolabeling for
phosphorylated-cPLA2 (p-cPLA2) and COX. In the both side of the
L5 DRG after nerve injury, COX-1-immunoreactivity (COX-1-IR)
was present mainly in small-sized neurons, whereas no COX-2-IR
was observed (Fig. 1A), consistent with previous studies [19,20].
Thus, we examined the effect of the selective COX-1 inhibitor SC-
560 [21] on the development of nerve injury-induced tactile
allodynia. Vehicle-treated rats with an L5 nerve injury displayed a
marked decrease in paw withdrawal threshold at the ipsilateral side
after nerve injury (p,0.001) (Fig. 1B). Similarly, nerve-injured rats
that had been treated with SC-560 showed a decreased paw
withdrawal threshold (p,0.001) and there were no significant
differences in the threshold of ipsilateral side between the vehicle-
and SC-560-treated group (Fig. 1B). We also found that most of
neurons with the translocated p-cPLA2 were not double-labeled
with COX-1-IR (169/251, 67.3% of p-cPLA2-translocated neu-
rons) (Fig. 1C). In a small group of DRG neurons, especially small-
sized neurons, both types of immunoreactivity were observed, but
their subcellular localizations were different: COX-1-IR was
observed in the perinuclear area where p-cPLA2-IR was not
accumulated (Fig. 1D). Next, to investigate the involvement of LOX
in nerve injury-induced tactile allodynia, we examined the effects of
the 5-LOX inhibitor AA-861 [22] and the 12- and 15-LOX
inhibitor baicalein [23,24] and found that AA-861- and baicalein-
treatedratsdisplayed a decrease in paw withdrawal thresholdwitha
similar time course to that of vehicle-treated rats (Fig. 2A, B). There
were no significant differences in the threshold between the vehicle-
and the LOX inhibitor-treated groups. The doses of the COX and
LOX inhibitors used in this study are approximately equivalent to
(or even higher than) doses that are known to inhibit behavioral
responses mediated by COX [25,26] and LOX [27,28], respec-
tively. Thus, these results suggest that COX and LOX in the DRG
may not be involved in nerve injury-induced tactile allodynia.
Effects of PAFR and LPAR antagonists on nerve injury-
induced tactile allodynia
To determine the role of lysophospholipid-derived lipid
mediators such as PAF and LPA in nerve injury-induced tactile
allodynia, we administered PAFR and LPA receptor (LPAR)
Figure 1. A COX inhibitor does not prevent the development of
tactile allodynia after nerve injury. A. Immunofluorescence
labeling of COX-1 and COX-2 proteins in the L5 DRG 14 days after
nerve injury demonstrated that immunoreactivity of COX-1, but not
COX-2, was present mainly in small-sized neurons. Scale bar, 50 mm. B.
The COX-1 inhibitor SC-560 (20 nmol/10 ml) administered through a
catheter whose tip was positioned near the L5 DRG once daily for 14
days did not suppress the development of nerve injury-induced a
decrease in the paw withdrawal threshold of tactile stimulation using
von Frey filaments. ***p,0.001 compared with the threshold of the
vehicle-treated group on day 0. {{{p,0.001 compared with the
threshold of the inhibitor-treated group on day 0. Data are presented as
mean 6 SEM of the paw withdrawal threshold of five animals. C.
Double immunofluorescence labeling of p-cPLA2 with COX-1 in L5 DRG
neurons 14 days after nerve injury showed that most of neurons with
the translocated p-cPLA2 were not double-labeled with COX-1-IR. Scale
bar, 50 mm. D. Highly magnified pictures of large and small diameter
DRG neurons demonstrated that in large neurons, p-cPLA2 was not co-
expressed with COX-1-IR. In small neurons, the subcellular localizations
of p-cPLA2 and COX-1-IR were different: COX-1-immunoreactivity was
observed in the perinuclear area where p-cPLA2- immunoreactivity was
not accumulated. Scale bars, 20 mm.
doi:10.1371/journal.pone.0010467.g001
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LPA biosynthetic enzymes are not available. We injected the
PAFR antagonist CV-3988 [29] and the LPA1R and LPA3R
antagonist Ki16425 [30] near the L5 DRG and found that CV-
3988 and Ki16425 significantly reduced the development of tactile
allodynia (CV-3988, p,0.001; Ki16425, day 3: p,0.01, day 7:
p,0.001, day 14: p,0.05) (Fig. 3A, B). By contrast, such
suppressing effect of CV-3988 on allodynia development was not
observed when CV-3988 was administered to the lumbar
enlargement of the spinal cord (where injured DRG neurons
project) (Fig. S1), suggesting that the anti-allodynic effect of the
PAFR antagonist may predominantly involve PAFRs expressed in
the DRG rather than in the spinal cord. In addition, CV-3988
treatment did not suppress thermal hyperalgesia (Fig. S2). Since
our previous study showed that acute inhibition of cPLA2
produces an alleviation of existing tactile allodynia [5], we then
examined whether pharmacological blockade of PAFRs and
LPARs could also be effective in treating existing allodynia. A
single administration of CV-3988 near the DRG 7 days after nerve
injury also partially reduced the expression of tactile allodynia
within 60 min (p,0.001) (Fig. 4A), whereas the decreased paw
withdrawal threshold at day 7 after nerve injury was not reversed
Figure 2. LOX inhibitors do not prevent the development of tactile allodynia after nerve injury. A, B. The 5-LOX inhibitor AA-861
(20 nmol/10 ml) (A) and the 12- and 15-LOX inhibitor baicalein (20 nmol/10 ml) (B) administered through a catheter whose tip was positioned near the
L5 DRG once daily for 14 days did not suppressed the development of nerve injury-induced tactile allodynia. **p,0.01, ***p,0.001 compared with
the threshold of the vehicle-treated group on day 0. {{p,0.01, {{{p,0.001 compared with the threshold of the inhibitor-treated group on day 0. All
data are presented as mean 6 SEM of the paw withdrawal threshold of five animals.
doi:10.1371/journal.pone.0010467.g002
Figure 3. PAFR and LPAR antagonists suppress the development of tactile allodynia by injury to the L5 spinal nerve. A, B.
Administration of PAFR antagonist CV-3988 (10 nmol/10 ml) (A) and the LPAR antagonist Ki16425 (10 nmol/10 ml) (B) through a catheter whose tip
was positioned near the L5 DRG once daily for 14 days after nerve injury suppressed the development of tactile allodynia. **p,0.01, ***p,0.001
compared with the threshold of the vehicle-treated group on day 0. {{p,0.01, {{{p,0.001 compared with the threshold of the antagonist-treated
group on day 0. #p,0.05, ##p,0.01, ###p,0.001 compared with the threshold of the vehicle-treated group at each time point. All data are
presented as mean 6 SEM of the paw withdrawal threshold of five to eight animals.
doi:10.1371/journal.pone.0010467.g003
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previous study [12,31]. Alterations in motor behavior after CV-
3988 and Ki16425 treatment were not observed (data not shown).
These results thus indicate that the PAFR has an important role in
the development and maintenance of tactile allodynia whereas the
LPAR in the DRG is important only for the development of tactile
allodynia.
Lyso-PAF-acetyltransferase LPCAT2 expression in the
DRG
Because a mechanism underlying LPAR-mediated tactile
allodynia has been previously demonstrated [12,31], in the present
study we investigated the role of the PAF-PAFR system in the
DRG. First, we examined whether DRG neurons with activated
cPLA2 express the lyso-PAF-acetyltransferase LPCAT2, a critical
enzyme that produces PAF [32,33,34]. However, it is difficult to
perform double-immunolabeling of DRG sections with p-cPLA2
and LPCAT2 antibodies, because they were raised in the same
host species (rabbit). Thus, in this experiment, we used two
adjacent DRG sections and singly immunostained one section with
each antibody. We observed DRG neurons that were positive for
both p-cPLA2 and LPCAT2 in the injured DRG 7 days after
nerve injury (indicated by arrowheads, Fig. 5). These results
suggest that LPCAT2 and activated cPLA2 are co-expressed in the
injured DRG. In addition, we observed many small cells that are
strongly positive to LPCAT2-IR around DRG neurons, and,
surprisingly, these are not overlapped with p-cPLA2-IR (indicated
by arrows, Fig. 5). It remains unclear whether the role of LPCAT2
in these small cells in neuropathic pain, and further investigations
will be needed to clarify its role.
Upregulation of the PAFR in the DRG after peripheral
nerve injury
We next examined the level of PAFR mRNA in total RNA
extracts from the L5 DRG ipsilateral and contralateral to an injury
to the L5 spinal nerve. We found that the expression of PAFR
mRNA in the ipsilateral DRG was markedly increased after nerve
injury (Fig. 6A). A significant increase was observed from day 3 after
injury (p,0.01 compared with the value of the contralateral
hindpaw) and PAFR mRNA levels peaked on day 14 (day 7:
p,0.01, day 14: p,0.001 compared with the value of contralateral
hindpaw and day 7: p,0.01, day 14: p,0.001 compared with that
of naı ¨ve group) (Fig. 6A). The upregulation of PAFR mRNA
expression on day 14 was not suppressed by CV-3988 administered
for 14 days (116% of the ipsilateral DRG of vehicle-treated rats). In
in situ hybridization analysis, we found that the intensity of PAFR
mRNA signals and the number of cells with strong signal of PAFR
mRNA were increased in the ipsilateral DRG 7 days after nerve
injury (Fig. 6C) compared with the contralateral DRG (Fig. 6B).
The expression of PAFR mRNA was increased in the cells
(arrowheads) surrounding DRG neurons (indicated as ‘N’) in the
ipsilateral DRG (Fig. 6C). Such specific signals of PAFR mRNA
were not seen in sections hybridized with a corresponding sense
probe (Fig. 6D). In addition, we performed in situ hybridization
using another sets of probes (NM_053321 positioned at 2518-3111
bases), and similar data of PAFR mRNA were observed (data not
shown). We validated the hybridization efficiency of antisense and
sense probes used in this study with the spleen sections where the
PAFR expression is known to be high [35] (Fig. S3). To identify the
type of cells expressing PAFR, we performed in situ hybridization
combined with immunohistochemistry for the macrophages/
microglia marker Iba1 (ionized calcium-binding adapter mole-
cule-1) and the satellite cells marker GFAP (glial fibrillary acidic
protein). We showed that the PAFR mRNA signals in the injured
DRG were restricted to cells labeled with Iba1 (Fig. 6E,
arrowheads), but not GFAP (Fig. 6F; GFAP, arrows; PAFR mRNA,
arrowheads). These results indicate that PAFR expression in the
DRG is upregulated in macrophages after nerve injury.
Attenuation of nerve injury-induced tactile allodynia in
pafr
2/2 mice
To precisely determine the functional relevance of PAFR, we
used PAFR-deficient mice (pafr
2/2 mice) [36]. pafr
2/2 mice
showed no major defects in basal mechanical sensitivity or motor
coordination in the rotarod test [37]. Wild-type mice with an L5
nerve injury showed a progressively decreased paw withdrawal
threshold (day 1: p,0.01, day 3, 7, 10 and 14: p,0.001) (Fig. 7).
There were significant differences in the threshold between wild-
type and pafr
2/2 mice (day 7: p,0.01, day 10 and 14: p,0.05)
Figure 4. Inhibition of PAFR induces a relieving effect on
existing tactile allodynia. A. The decrease in paw withdrawal
threshold was attenuated by a single administration of CV-3988
(10 nmol/10 ml) (A), but not Ki16425 (10 nmol/10 ml) (B), through a
catheter whose tip was positioned near the L5 DRG on day 7 after nerve
injury. ***p,0.001, {{{p,0.001 compared with pre-injury baseline
(Pre). ###p,0.001 compared with the threshold on day 7. n.s. means
‘‘not significant’’. All data are presented as mean 6 SEM of the paw
withdrawal threshold of five to eight animals.
doi:10.1371/journal.pone.0010467.g004
Figure 5. LPCAT2 is expressed in DRG neurons positive to p-
cPAL2 following peripheral nerve injury. Immunohistochemical
analysis using two adjacent DRG sections (singly immunostained one
section with p-cPLA2 or LPCAT2 antibody) revealed that there were DRG
neurons positive for both p-cPLA2 and LPCAT2 in the injured DRG
(arrowheads) 7 days after nerve injury. Arrows indicate unknown cells
that were strongly positive to LPCAT2-IR and negative to p-cPLA2.-IR.
Scale bar, 50 mm.
doi:10.1371/journal.pone.0010467.g005
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2/2 mice was decreased after
injury (Fig. 7). Ablation of PAFRs did not change the paw
withdrawal threshold at the side contralateral to the nerve injury
(Fig. 7). Thus, PAFR might be required for tactile allodynia
following peripheral nerve injury.
Reduction of upregulation of TNFa and IL-1b expression
in pafr
2/2 mice
TNFa and IL-1b are proinflammatory cytokines that have been
reported to be upregulated in the DRG following peripheral nerve
injury [16,17,38] and be produced via PAFRs in non-neuronal
cells [39,40]. We predicted that the loss of PAFRs could affect the
levels of TNFa and IL-1b in the L5 DRG. To address this, we
examined the levels of mRNA of these cytokines in the DRG after
nerve injury using real-time RT-PCR. The expression levels of
these mRNAs at the ipsilateral DRG of wild-type mice was much
higher than at the contralateral side on day 7 (TNFa: p,0.01, IL-
1b: p,0.001) (Fig. 8A, B), but pafr
2/2 mice failed to show
upregulation of these cytokines and there were significant
differences in these expression level of ipsilateral side between
wild-type and pafr
2/2 mice (TNFa: p,0.05, IL-1b: p,0.01).
Figure 6. PAFR mRNA is upregulated in the DRG following peripheral nerve injury. A. Real-time PCR analysis revealed that PAFR
mRNA expression in total RNA extract from the L5 DRG was markedly increased after peripheral nerve injury. The bar graphs show the average
fold increase in the level of PAFR mRNA expression in the DRG compared with the mean expression level of PAFR mRNA in naı ¨ve rats. Each
measurement was normalized to GAPDH content. **p,0.01, ***p,0.001 compared with naı ¨ve rats. {{p,0.01, {{{p,0.001 compared with the
contralateral side. All data are presented as mean 6 SEM of five individual animals. B-D. DIG-labeled antisense (B: contralateral, C: ipsilateral) and
sense (D: ipsilateral) probes specific for PAFR mRNA were visualized by in situ hybridization in the rat DRG 7 days after nerve injury. Strong PAFR
mRNA signals were observed in the cells surrounding DRG neurons in the ipsilateral DRG 7 days after nerve injury. Arrowheads show PAFR
mRNA-positive cells. ‘N’ indicates neuronal cells. Similar results were observed in each of three experiments. Scale bar, 50 mm. E,F. In situ
hybridization combined with immunohistochemistry for the macrophages/microglia marker Iba1 and the satellite glia marker GFAP was
performed. PAFR mRNA signals overlapped with Iba1-IR (arrowheads, E) but not with GFAP-IR (GFAP: white arrowheads, PAFR: white arrows, F).
Scale bar, 25 mm.
doi:10.1371/journal.pone.0010467.g006
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contralateral DRG. These results indicate that PAFRs might
contribute to tactile allodynia via TNFa and IL-1b production in
the DRG following nerve injury.
Effect of PAF injection on paw withdrawal threshold and
cytokine production in the DRG
We determined whether injection of PAF in the absence of
nerve injury is sufficient to produce tactile allodynia and to
upregulate cytokine expression in the DRG. A single injection of
PAF near the DRG of naı ¨ve rats caused a decrease in the paw
withdrawal threshold to mechanical stimulation in a dose-
dependent manner (Fig. 9A). The threshold began to decrease
15 min after PAF injection and peaked at 45–60 min, then
gradually recovered over 4 h (Fig. 9A). The decrease in the
withdrawal threshold induced by PAF was inhibited by pretreat-
ment with CV-3988 (p,0.01) (Fig. 9B). We then performed real-
time RT-PCR analysis using the DRG of rats that had been
injected with PAF. The expression of mRNAs for TNFa and IL-
1b was increased 45 min after PAF injection (Fig. 9C, D), when
the threshold was markedly reduced. This effect was also
prevented by pretreatment with CV-3988 (Fig. 9C, D). These
results suggest that administering PAF near the DRG causes a
decrease in the withdrawal threshold and production of TNFa and
IL-1b via PAFR.
Discussion
In the present study, we provide the first evidence that in the
DRG, PAFR is important in the pathogenesis of tactile allodynia,
a major behavioral consequence of nerve injury, and are
responsible for production of proinflammatory cytokines such as
TNFa and IL-1b.
We have previously shown that cPLA2 is translocated to the
plasma membrane mainly in medium- to large-diameter DRG
neurons [5], but COX-1 was present around the perinuclear
region of small-sized DRG neurons. In addition, our behavioral
studies demonstrated that administering the COX-1 inhibitor SC-
560 near the injured DRG showed no anti-allodynic effect at doses
that are considered to inhibit this enzyme [25,26]. A previous
study reported that administration of SC-560 to the lumbar
enlargement of the spinal cord at a higher dose than our study
prevented a decrease in the paw withdrawal threshold after nerve
injury [41], which seems to be partly inconsistent with our present
results. However, peripheral nerve injury causes an increase in
COX-1 and COX-2 expression in the spinal cord [42,43], but not
in the DRG, and a high dose of SC-560 also slightly inhibits
COX-2 [21]. Thus, it is possible that the discrepancy in the effect
of SC-560 on tactile allodynia might be explained by the difference
in dose and region of drug administration. These results thus
suggest that COX in the DRG is not primarily involved in the
cPLA2-dependent tactile allodynia. These data may also provide a
putative explanation for the resistance or controversial effects of
COX inhibitors on allodynic behavior reported in both animals
and patients with neuropathic pain [44].
Similar to SC-560, neither the 5-LOX inhibitor AA-861 nor
the 12- and 15-LOX inhibitor baicalein showed the inhibitory
effect on nerve injury-induced tactile allodynia. Products of
lipoxygenases such as leukotrienes, hydroxyeicosatetraenoic acids
(HETEs) and hydroperoxyeicosatetraenoic acids (HPETEs) have
been implicated in mediating inflammatory nociception because
they are produced during inflammation [45] and cause
hyperalgesia when injected intradermally [46,47], but so far
there have been no reports that clearly show the involvement of
lipoxygenases in tactile allodynia. These findings and the data
presented here suggest that in the DRG, LOX does not also play
a major role in nerve injury-induced tactile allodynia as in the
case of COX, while we can not completely exclude the possibility
that COX and LOX in the spinal cord are involved in tactile
Figure 7. Deletion of pafr reduces tactile allodynia. While wild-type
mice with an L5 nerve injury showed a progressively decreased paw
withdrawalthreshold,pafr
2/2miceshowed an attenuation of the decrease
in paw withdrawal threshold after nerve injury. **p,0.01, ***p,0.001
compared with the threshold of wild-type mice on day 0. {{p,0.01
compared with the threshold of pafr
2/2 mice on day 0. #p,0.05,
##p,0.01 compared with the threshold of the wild-type mice at each
time point. All data are presented as mean 6 SEM of six to eight animals.
doi:10.1371/journal.pone.0010467.g007
Figure 8. Upregulation of TNFa and IL-1b gene expression in
the DRG is reduced in pafr
2/2 mice. A, B. Real-time PCR analysis
demonstrated that following nerve injury, the expression of TNFa (A)
and IL-1b (B) mRNAs in the ipsilateral DRG of wild-type mice was much
higher than in the contralateral side on day 7. However, pafr
2/2 mice
failed to show upregulation of these cytokines and there were
significant differences in these expressions of the ipsilateral side
between wild-type and pafr
2/2 mice. Each measurement was
normalized to 18S mRNA content. **p,0.01, ***p,0.001 compared
with the contralateral side of wild-type mice. #p,0.05, ##p,0.01
compared with the ipsilateral side. n.s. means ‘‘not significant’’. All data
are presented as mean 6 SEM of six to eight animals.
doi:10.1371/journal.pone.0010467.g008
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mainly in small-diameter DRG neurons and LOX products
activate capsaicin receptors in primary sensory neurons [9,10],
COX and LOX in the DRG may participate in thermal
hyperalgesia after nerve injury.
The crucial role of PAFR in neuropathic pain was demonstrat-
ed for the first time by the data obtained from the behavioral
analyses using pharmacological and genetic tools. Administration
of the PAFR antagonist CV-3988 near the injured DRG reduced
the development and expression of nerve injury-induced tactile
allodynia. By contrast, the reducing effect of the development of
tactile allodynia by administration of CV-3988 to the lumbar
enlargement of the spinal cord was much less than that by
injection of the antagonist near the DRG. Furthermore, DRG
neurons with activated cPLA2 also expressed the lyso-PAF-
acetyltransferase LPCAT2, a critical enzyme that produces PAF
[32,33,34]. Our data from real-time RT-PCR analyses showed
that PAFR gene expression was increased in the ipsilateral DRG
after nerve injury. These findings thus suggest that the PAF/PAFR
system may be activated in the injured DRG and contribute to
nerve injury-induced tactile allodynia, although a possible
involvement of PAFR in the spinal cord can not be completely
excluded [13]. Moreover, our in situ hybridization experiments
revealed that following peripheral nerve injury a marked increase
in PAFR mRNA expression was seen mainly in non-neuronal cells
positive to Iba1. It is conceivable that peripheral nerve injury
causes the transcriptional upregulation of PAFR in macrophages
in the DRG. Alternatively, infiltration of macrophages expressing
PAFR in the DRG after nerve injury might result in the
upregulation of PAFR mRNA, because PAFR is expressed in
macrophages [35] and is involved in macrophage chemotaxis [48]
and the number of macrophages in the DRG is increased
following peripheral nerve injury [49]. Interestingly, PAFR-
deficient mice showed a marked suppression of the upregulation
of TNFa and IL-1b expression in the injured DRG. This is
consistent with the notion that macrophages are one of the major
sources of these proinflammatory cytokines and regulate pain
signaling [49,50,51,52], although it remains unknown whether
PAFR activation leads to upregulation of proinflammatory
cytokine expression in macrophages.
Figure 9. Injection of PAF near the DRG induces a decrease in the paw withdrawal threshold and upregulation of TNFa and IL-1b
mRNAs. A. Paw withdrawal threshold was decreased by single administration of several different doses of PAF near the DRG in normal rats. *p,0.05,
**p,0.01, ***p,0.001 compared with the threshold of the vehicle-treated group. B. The PAF-induced decrease in paw withdrawal threshold was
suppressed by pretreatment with CV-3988. ***p,0.001 compared with the threshold of the vehicle-treated group. ##p,0.01 compared with the
threshold of the PAF-treated group. n.s. means ‘‘not significant’’. C, D. Real-time PCR analysis showed that administration of PAF near the DRG
increased expression of TNFa (C) and IL-1b (D) mRNAs in the DRG 45 min after the administration. The bar graphs show the average fold increase in
the level of TNFa and IL-1b mRNAs in the DRG compared with the mean expression level of these mRNAs in the vehicle-treated group. Each
measurement was normalized to 18S mRNA content. *p,0.05, **p,0.01, ***p,0.001 compared with the vehicle-treated group. #p,0.05,
###p,0.001 compared with the PAF-treated group. n.s. means ‘‘not significant’’. All data are presented as mean 6 SEM of four to six animals.
doi:10.1371/journal.pone.0010467.g009
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[16,17] are upregulated in the DRG following peripheral nerve
injury and are implicated in tactile allodynia. Increased synthesis
and release of TNFa and IL-1b can directly modulate neuronal
activity and elicit spontaneous action potential discharges in the
DRG [49]. TNFa enhances tetrodotoxin-resistant Na
+ currents in
DRG neurons through TNF receptor 1 [57]. Both injured and
adjacent uninjured primary afferent neurons become more
sensitive to TNFa after spinal nerve ligation [18]. Similarly, IL-
1b application has been shown to increase the excitability of
sensory neurons by potentiating voltage-dependent Na
+ currents
[58]. Therefore, these cytokines in the injured DRG might be
involved in sensitization of primary sensory neurons that link to
nerve injury-induced tactile allodynia. It remains unclear whether
the expression of these cytokines results from PAFR activation in
non-neuronal cells in the DRG. In the future, by generating using
cell type-specific PAFR-knockout mice, and by studying their
phenotypes, this issue will be determined.
LPA could also be a candidate signaling molecule that is
responsible for nerve injury-induced tactile allodynia. Our
behavioral study demonstrated that injection of the LPAR
antagonist Ki16425 near the injured DRG reduced the develop-
ment, but not maintenance, of tactile allodynia, which is consistent
with a previous study [12]. Because among LPARs, LPA1Ri s
mainly expressed in the DRG and LPA1R-deficient mice attenuate
nerve injury-induced tactile allodynia [12]. LPA1Rs mediate
demyelination and upregulate the expression of the a2d1 subunit
of the voltage-gated calcium channel in the DRG [12], and these
might be the mechanisms underlying LPA-dependent tactile
allodynia. Furthermore, LPA increases the intracellular calcium
concentration in adult DRG neurons [59] and intraplantar
injection of LPA causes a nociceptive flexor response [60],
suggesting that LPA could produce direct effects on primary
afferent neurons and modulate nociceptive responses.
Based on the results obtained from our present and previous
studies, we proposed the following mechanism (Fig. 10). After
peripheralnerve injury,cPLA2 isactivated byCa
2+signalingevoked
by P2X3 or P2X2/3 receptors (subtype of ionotropic purinergic
receptors) [5]. These receptors are activated by extracellular ATP,
which presumably released from neighboring cells such as satellite
glia. Activity of voltage-gated Ca
2+ channels (VDCC) is also
involved in cPLA2 activation [61]. The Ca
2+-dependent cPLA2
activation is mediated by Ca
2+/calmodulin-dependent protein
kinase II (CaMKII) [61]. cPLA2 supply lyso-PAF, a precursor of
PAF, which in turn converts into PAF by LPCAT2 (although the
role of LPCAT2 expressed in unknown cells in the DRG remains
unclear). PAF may be released from DRG neurons and then
activatesPAFRexpressedinmacrophages.ActivationofPAFRmay
lead to production and release of proinflammatory cytokines. These
cytokines increasetheexcitabilityofDRGneuronsthat linkto nerve
injury-induced tactile allodynia.
In summary, the present study provided the first evidence that
the activation of the PAFR may be a key event in the development
and maintenance of tactile allodynia and production of proin-
flammatory cytokines such as TNFa and IL-1b in the DRG. Thus,
blocking the PAFR might be a new therapeutic target for treating
neuropathic pain. Importantly, basal pain sensitivity was not
altered in pafr
2/2 mice, suggesting the possibility of a therapeutic
benefit of blocking PAFRs in the treatment of tactile allodynia
without affecting normal pain sensitivity. As the PAFR has been
implicated in other neurodegenerative disorders such as ischemia
[62] and multiple sclerosis [39], interfering with PAFRs could be a
therapeutic strategy widely applicable to central nervous system
diseases.
Materials and Methods
All animal experiments were conducted according to relevant
national and international guidelines ‘Act on Welfare and
Management of Animals’ (Ministry of Environment of Japan)
and ‘Regulation of Laboratory Animals’ (Kyushu University), and
under the protocols approved by the Institutional Animal Care
and Use committee review panels at Kyushu University and The
University of Tokyo.
Animals
Male Wistar rats (250–270 g, Japan SLC, Shizuoka, Japan) and
wild-type and pafr
2/2 mice [36] were used. Animals were housed
in individual and groups of 2,3 per cage at a temperature of
2261uC with a 12-h light-dark cycle (light on 8:30 to 20:30), and
fed food and water ad libitum.
Neuropathic pain model
We used the spinal nerve injury model [63] with some
modifications [64]: in male Wistar rats a unilateral L5 spinal
nerve was tightly ligated and cut just distal to the ligature. For the
experiments using mice, the left L5 spinal nerve was transected
[65]. The mechanical allodynia was assessed by using calibrated
von Frey filaments (0.4–15.1 g for rats, 0.02–2.0 g for mice;
Stoelting, Wood Dale, IL, USA) and the paw withdrawal threshold
was determined as described previously [64].
Drug treatment
Rats were implanted with catheters for drug injection near the
L5 DRG according to the method described previously [64,65].
Under isoflurane anesthesia, a sterile 32 gauge catheter (Re-
CathCo, Allison Park, PA, USA) was inserted into the intrathecal
space through the atlanto-occipital membrane and to the L4 or L5
DRG and externalized through the skin [5]. After the experi-
ments, we confirmed that the tip of the catheter was positioned
near the L5 DRG. Rats were injected with each drug through the
catheter using a 25 ml Hamilton syringe with a 30-gauge needle
once a day from day 0 (just before the nerve injury) to day 13. The
drugs used in this study are listed below: SC-560 (20 nmol/10 ml,
Calbiochem, San Diego, CA, USA), AA-861 (20 nmol/10 ml,
Sigma, St Louis, MO, USA), baicalein (20 nmol/10 ml, Calbio-
chem), CV-3988 (10 nmol/10 ml, Biomol, Plymouth Meeting, PA,
USA) and Ki16425 (10 nmol/10 ml, Sigma). The paw withdrawal
threshold was tested 21–24 hr after the injection of each drug at 1,
3, 7 and 14 days post-injury. For the experiment in which the
effect of a single administration of CV-3988 or Ki16425 on the
established allodynia was examined on day 7 after nerve injury,
behavioral test was performed immediately before and after the
injection of CV-3988 (10 nmol/10 ml) or Ki16425 (10 nmol/
10 ml). To examine the effect of PAF on pain behavior, the paw
withdrawal threshold was assessed before and after a single
injection of PAF near the DRG of naı ¨ve rats. Rats were injected
with CV-3988 (10 nmol/10 ml) through the catheter 10 min
before the injection of PAF.
Immunohistochemistry
Rats were deeply anesthetized by pentobarbital (100 mg/kg,
i.p.) and perfused transcardially with 4% paraformaldehyde. DRG
sections were removed, postfixed with the same fixative, and
placed in 30% sucrose solution for 24 hr at 4uC. The DRG
sections (15 mm) were incubated in a blocking solution [3%
normal goat serum/0.3% Triton X-100/phosphate-buffered
saline (PBS) (2)] and then with anti-phospho-cPLA2 (anti-p-
cPLA2) antibody (1:1000, Cell Signaling, Beverly, MA, USA), anti-
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anti-COX-2 antibody (1:50, Cayman chemical), and anti-
LPCAT2 antibody (1:500, [34]). Identification of neurons was
performed with a marker of neurons, microtubule associated
protein 2 (1:1000, Chemicon, Temecula, CA, USA). Following
incubation, the DRG sections were incubated with anti-rabbit
immunoglobulin G (IgG)-conjugated Alexa Fluor 488 or anti-
mouse IgG-conjugated Alexa Fluor 546 (1:1000, Molecular
Probes, Eugene, OR, USA). The sections were then analyzed by
a confocal microscope (LSM510, Zeiss, Oberkochen, Germany).
DRG neurons were characterized as small (,600 mm
2), medium
(600-1200 mm
2), and large (.1200 mm
2)-sized neurons according
to their cross-sectional areas [66].
Real-time reverse transcription-PCR
Rats and mice were deeply anesthetized with pentobarbital,
perfused transcardially with PBS, and the L5 DRG was removed
immediately. Total RNA from the L5 DRG was extracted by using
Trisure (Bioline, Danwon-Gu, Korea) according to manufacturer’s
protocol and purified using RNeasy mini plus kit (QIAGEN,
Valencia, CA, USA). The amount of total RNA was quantified by
measuring OD260 using a Nanodrop spectrophotometer (Nano-
drop, Wilmington, DE). For reverse transcription, 100 ng of total
RNA was transferred to the reaction with Prime Script reverse
transcriptase (Takara, Kyoto, Japan) and random 6-mer primers.
Quantitative PCR was carried out with Premix Ex Taq (Takara)
using a 7500 real-time PCR system (Applied Biosystems, Foster
City, CA) according to protocol of the manufacturer, and the data
were analyzed by 7500 System SDS Software 1.3.1 (Applied
Biosystems) using the standard curve method. The TaqMan probe,
forward primer and reverse primer used in this study were designed
as follows: rat PAFR, probe, 59-FAM- ATCTCACCGTGGCG-
GACCTGCTCT-TAMRA-39, forward, 59-CCCGTCCAAGAA-
ACTGAATGAG-39, and reverse, 59-TCGCCCTCGTTGGAG-
TAATAGA-39; mouseTNFa,probe,59-FAM-TACGTGCTCCT-
CACCCACACCGTCA-TAMRA-39, forward, 59-GTTCTCTT-
CAAGGGACAAGGCTG-39, and reverse, 59-TCCTGGTATGA-
GATAGCAAATCGG-39; mouse IL-1b,p r o b e ,5 9-FAM-TGC-
AGCTGGAGAGTGTGGATCCCAA-TAMRA-39, forward, 59-
GAAAGACGGCACACCCACC-39, and reverse, 59-AGACAA-
ACCGCTTTTCCATCTTC-39;ratTNFa,p r o b e ,5 9-FAM-CGT-
AGCCCACGTCGTA-TAMRA-39, forward, 59-GACCCTCA-
CACTCAGATCATCTTCT-39, and reverse, 59- GGTACAGCC-
CATCTGCTGGTA-39; rat IL-1b,p r o b e ,5 9-FAM-TCTCCA-
CCTCAATGGACAGAACATAAGCCA-TAMRA-39, forward,
59-AAATGCCTCGTGCTGTCTGA-39, and reverse, 59-GTCG-
TTGCTTGTCTCTCCTTGTAC-39. The primers and probe for
GAPDH and 18S mRNA were obtained from Applied Biosystems.
In situ hybridization
Digoxigenin (DIG)-labeled sense and antisense RNA probes
were prepared from the sequence of rat pafr mRNA (GenBank
accession number: NM_053321) positioned at 1178–1819 bases.
Rats were anesthetized and perfused transcardially with Tissue
Fixative (Genostaff, Tokyo, Japan) 7 day after nerve injury. DRG
sections were removed and again fixed with the same fixative.
Paraffin-embedded tissues (6 mm) were dewaxed with xylene and
rehydrated. After proteinase K treatment (8 mg/ml, 30 min, 37uC)
and acetylation by acetic anhydride (0.25%), hybridization was
performed with sense and antisense probes at concentrations of
300 ng/ml at 60uC for 16 h. After hybridization, a series of
washing was performed, followed by RNase treatment (50 mg/ml,
30 min, 37uC). The sections were blocked with 0.5% blocking
reagent (Roche, Indianapolis, IN, USA) in Tris-buffered saline
containing Tween 20 and incubated with anti-DIG alkaline
phosphatase conjugate (1:1000, Roche) for 2 h at room temper-
ature. Coloring reactions were performed with nitro blue
tetrazolium chloride/5-bromo-4-chloro-3-indolyl phosphate solu-
tion (NBT/BCIP) (Sigma, St. Louis, MO, USA) overnight. The
sections were counterstained with Kernechtrot stain solution
(Mutoh, Tokyo, Japan) and then mounted with Malinol (Mutoh).
Non-neuronal and neuronal cells with a higher violet intensity
Figure 10. Schematic representation of the proposed mechanism underlying the PAF/PAFR system-mediated neuropathic pain
after peripheral nerve injury. After peripheral nerve injury, cPLA2 is activated by Ca
2+ signaling evoked by P2X3 or P2X2/3 receptors (subtype of
ionotropic purinergic receptors) and voltage-gated Ca
2+ channels (VDCC). The Ca
2+-dependent cPLA2 activation involves Ca
2+/calmodulin-dependent
protein kinase II (CaMKII). cPLA2 supply lyso-PAF which in turn converts into PAF by the lyso-PAF-acetyltransferase LPCAT2. PAF activates PAFR
expressed in macrophages. Activation of PAFR may lead to production and release of proinflammatory cytokines, TNFa and IL-1b. These cytokines
may increase the excitability of DRG neurons that link to nerve injury-induced tactile allodynia.
doi:10.1371/journal.pone.0010467.g010
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positively labeled for PAFR mRNA. For immunohistochemistry as
a second staining after ISH, the sections were treated 3%
hydrogen peroxide in PBS for 15 min, and Protein Block (Dako).
Sections were incubated either with the anti-Iba1 rabbit polyclonal
antibody (1:1000, Wako) or anti-GFAP rabbit polyclonal antibody
(1:500, Dako) at 4uC for overnight. After washing with TBS,
sections were incubated with biotin-conjugated goat anti-rabbit
IgG (Dako) for 30 min at room temperature, followed by the
addition of peroxidase conjugated streptavidin (Nichirei) for
5 min. Peroxidase activity was visualized by diaminobenzine.
Statistical analysis
All data are presented as means 6 SEM. The statistical
significance of difference between values was determined by
Student’s t test or analysis of variance (ANOVA) with appropriate
post hoc tests. A p value less than 0.05 was considered to be
statistically significant.
Supporting Information
Figure S1 The effect of the PAFR antagonist CV-3988
administered to the lumbar enlargement of the spinal cord on
the development of nerve injury-induced tactile allodynia. The
paw withdrawal threshold of tactile stimulation was examined
using von Frey filaments. CV-3988 or vehicle was administered
once daily for 7 days. ***p,0.001, #p,0.05 compared with pre-
injury baseline (Pre). n.s. means ‘‘not significant’’. All data are
presented as mean 6 SEM of the paw withdrawal threshold of
three animals.
Found at: doi:10.1371/journal.pone.0010467.s001 (0.06 MB TIF)
Figure S2 PAFR antagonist CV-3988 does not suppress the
development of thermal hyperalgesia induced by injury to the L5
spinal nerve. CV-3988 (10 nmol/10 ml) was administered near the
DRG once daily for 14 days after nerve injury. *p,0.05,
**p,0.01. All data are presented as mean 6 SEM of the paw
withdrawal latency to thermal stimulus of four to five rats.
Found at: doi:10.1371/journal.pone.0010467.s002 (0.05 MB TIF)
Figure S3 Validation of digoxigenin-labeled antisense (left) and
sense (right) RNA probes prepared from the sequence of rat pafr
mRNA (NM_053321 positioned at 1178-1819 bases) with the
spleen sections. Scale bar, 25 mm.
Found at: doi:10.1371/journal.pone.0010467.s003 (1.14 MB TIF)
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